A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: Feasibility, tolerability and clinical outcomes

Drug and Alcohol Review

Volumn 32, Issue 1, 2013, Pages 88-95

  Lee, Nicole ^a,b   Pennay, Amy ^a,c   Hester, Robert ^d   Mcketin, Rebecca ^e,f   Nielsen, Suzi ^a,g   Ferris, Jason ^a,h  

^a TURNING POINT ALCOHOL AND DRUG CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Methamphetamine; Modafinil; Randomised controlled trial; Withdrawal

Indexed keywords

BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; METHAMPHETAMINE; MODAFINIL;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PILOT STUDY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; YOUNG ADULT;

ADULT; AMPHETAMINE-RELATED DISORDERS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; PILOT PROJECTS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872288283     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2012.00473.x     Document Type: Article

References (35)

1. United Nations Office on Drugs and Crime. World drug report 2009. Vienna: United Nations Office on Drugs and Crime, 2010.
2. Australian Institute of Health and Welfare. 2007 National Drug Strategy Household Survey: detailed findings. Drug statistics series No. 22. Cat. No. PHE 107. Canberra: Australian Institute of Health and Welfare, 2008.
3. McKetin R, Kelly E, McLaren J. The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug Alcohol Depend 2006;85:198-204.
4. Brecht ML, Greenwell L, Anglin MD. Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002). J Subst Abuse Treat 2005;29:295-306.
5. McKetin R, Kelly E, Indig D. Characteristics of treatment provided for amphetamine use in New South Wales, Australia. Drug Alcohol Rev 2005;24:433-436.
6. Simon SL, Dacey J, Glynn S, Rawson R, Ling W. The effect of relapse on cognition in abstinent methamphetamine users. J Subst Abuse Treat 2004;27:59-66.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington DC: American Psychiatric Association, 2000.
8. Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend 2001;63:269-276.
9. Weiss RD, Griffin ML, Mazurick C, etal. The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. Am J Psychiatry 2003;160:1320-1325.
10. Lee N, Rawson R. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008;27:309-317.
11. Pennay A, Lee N. Barriers to methamphetamine withdrawal treatment in Australia: findings from a survey of AOD service providers. Drug Alcohol Rev 2009;28:636-640.
12. Kenny P, Lee N, Harney A, Pennay A. Treatment utilisation and barriers to treatment: results of a survey of dependent methamphetamine users. Subst Abuse Treat Prev Policy 2011;6:3.
13. Heinzerling KG, Shoptaw S, Peck JA, etal. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006;85:177-184.
14. Cruickshank C, Montebello M, Dyer K, etal. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev 2008;27:326-333.
15. Jittiwutikan J, Srisurapanont M, Jarusuraisin N. Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai 1997;80:587-592.
16. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Aust N Z J Psychiatry 1999;33:94-98.
17. Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. Cochrane Database Syst Rev 2009;15:CD003021.
18. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008;35:334-342.
19. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2003;30:205-211.
20. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008;33:761-768.
21. Heinzerling KG, Swanson AN, Kim S, etal. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010;109:20-29.
22. Shearer J, Darke S, Rodgers C, etal. A double-blind, placebo controlled trial of modafinil (200mg/daily) for methamphetamine dependence. Addiction 2008;104:224-233.
23. Makris AP, Rush CR, Frederich RC, Kelly TH. Wake-promoting agents with different mechanisms of action: comparison effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004;42:185-195.
24. Morgan PT, Pace-Schott E, Pittman B, Stickgold R, Malison RT. Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry 2010;167:331-340.
25. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477-1502.
26. Villemagne VL, Yuan J, Wong DF, etal. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35, 428 positron emission tomography studies and direct in vitro determinations. J Neurosci 1998;18:419-427.
27. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry 1999;33:89-93.
28. McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM. Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. J Subst Abuse Treat 2008;34:443-449.
29. Kampman KM, Volpicelli JR, McGinnis DE, etal. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav 1998;23:449-461.
30. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005;100:1320-1329.
31. Ellis BW, Johns MW, Lancaster R, Raptopoulos P, Angelopoulos N, Priest RG. The St. Mary's Hospital Sleep Questionnaire: a study of reliability. Sleep 1981;4:93-97.
32. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;4:87-89.
33. McKnight PE. Missing data: a gentle introduction. In: Mcknight PE, ed. Methodology in the social sciences. New York: Guildford Press, 2007.
34. Australian Institute of Health and Welfare. Alcohol and other drug treatment services in Australia 2006-07: report on the National Minimum Data Set. Drug treatment series No. 8. Cat. No. HSE 59. Canberra: AIHW, 2008.
35. Morgenstern J, McKay JR. Rethinking the paradigms that inform behavioral treatment research for substance use disorders. Addiction 2007;102:1377-1389.